Clinical trials: Early and Locally Advanced Breast Cancer
HER2-positive Breast Cancer
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
To evaluate the pathology complete response rate (pathology Complete Response, pCR) of eribulin combined with trastuzumab + pertuzumab in neoadjuvant therapy for HER-2 positive early or locally advanced breast cancer.
- Trial name
- NCT05945368
- Testing
- Eribulin mesylate injection、Pertuzumab、Trastuzumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
This is a randomized, open-label, superiority, multicenter clinical trial for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer.
- Trial name
- NCT07797218
- Testing
- Docetaxel, Pyrotinib, Trastuzumab (Herceptin)
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
The goal of this clinical trial is to evaluate the efficacy and safety of SHR-A1811 plus pertuzumab in combination with or without albumin-paclitaxel neoadjuvant therapy for early or locally advanced HER2-positive breast cancer.
- Trial name
- NCT06927180
- Testing
- SHR-A1811, Pertuzumab, Albumin-Paclitaxel
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Henan Cancer Hospital
Early or Locally Advanced HER2-positive Breast Cancer
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive…
- Trial name
- Neo-Healer (NCT06747338)
- Testing
- KN026, HB1801, Pertuzumab
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Shanghai JMT-Bio Inc.
Breast Cancer (Early Breast Cancer), BRCA 1 Gene Mutation
Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer
This study was designed to evaluate the safety and efficacy of neoadjuvant therapy with mitomycin and carboplatin in patients with BRCA-associated locally advanced triple-negative breast cancer.
- Conditions
- Breast Cancer (Early Breast Cancer), BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
- Trial name
- MCarb-T (NCT07821229)
- Testing
- Neoadjuvant Chemotherapy (NACT)
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Breast Cancer
Follow-up in Early and Locally Advanced Breast Cancer Patients
A cross-sectional follow-up study of Early and Locally Advanced Breast Cancer patients after primary treatment.
- Trial name
- NCT03859453
- Where
- 28 sites in Belgium, France and 8 more
- Volunteers
- 830 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer Female
Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer
Prospective phase 2 study to evaluate the safety and efficacy of ultra-hypofractionated adjuvant radiotherapy in 5 fractions of 5.7 Gy in patients aged over 65 years.
- Trial name
- NCT05850637
- Testing
- adjuvant ultra-hypofractionated radiotherapy
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Prevent Senior Institute
Triple Negative Breast Cancer
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab (an engineered anti-programmed death-ligand 1 [PD-1] antibody) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy in participants…
- Trial name
- NCT04613674
- Testing
- Camrelizumab Plus Chemotherapy
- Where
- China
- Volunteers
- 441 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced Breast Cancer
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
Primary Objective: Determination of pathologic complete response (pCR) rates Secondary Objective: Determination of cardiac toxicity as measured by: composite of LVEF, longitudinal strain and troponin.
- Trial name
- NCT03329378
- Testing
- Docetaxel, Carboplatin, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
SHR-A1811, HER2-Postive Breast Cancer
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
Breast cancer is the most common malignancy in women, with approximately 20% classified as HER2-positive. Anti-HER2 blockade (trastuzumab plus pertuzumab) combined with chemotherapy constitutes the standard neoadjuvant regimen…
- Conditions
- SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer, Early Breast Cancer
- Trial name
- NCT07307287
- Testing
- SHR- A1811
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
ctDNA in HER2+ EBC Neoadjuvant Treatment
This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant…
- Trial name
- NCT07335081
- Testing
- pyrotinib, pertuzumab, trastuzumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer
Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients
The trial will be preceded by a pilot phase study in 5 patients. This will then be followed by the randomized 1:1 phase II trial testing the utility of regional cryotherapy in preventing or reducing paclitaxel-induced peripheral…
- Trial name
- NCT03429972
- Testing
- Elasto-Gel™, Paclitaxel
- Where
- Singapore
- Volunteers
- 51 people
- Sponsor
- National Cancer Centre, Singapore